Sign In
Buy MRK
$115.17
+0.270 (+0.235%)
At Close: Jun 16, 2026
Merck Reports Earnings Under Shadow of Keytruda Patent Cliff. What to Expect.
04:30pm, Wednesday, 29'th Oct 2025
Third quarter earnings are coming. The pharmaceutical maker's stock is down 12% this year.
The setup on earnings beyond tech
02:19pm, Wednesday, 29'th Oct 2025
The Investment Committee debate some non-mega cap names reporting in the next 24 hours.
Merck, Eisai discontinue late-stage study for liver cancer therapy
07:59am, Wednesday, 29'th Oct 2025
Merck and Japan's Eisai said on Wednesday they will shut down a late-stage study testing an experimental combination therapy to treat a type of liver cancer, after interim results showed the treatment
Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
07:00am, Wednesday, 29'th Oct 2025
RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma.
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA® (pembrol
Buy, Sell or Hold MRK Stock Ahead of Q3 Earnings? Things to Know
01:40pm, Tuesday, 28'th Oct 2025
MRK faces pressure from weak vaccine sales and rising competition, but strong oncology growth and new launches could support a rebound.
Healthy Returns: What to expect from Eli Lilly, Merck, Gilead and AbbVie third-quarter earnings
10:40am, Tuesday, 28'th Oct 2025
Eli Lilly, Merck, Gilead, Bristol Myers Squibb and AbbVie, among other pharmaceutical companies, are slated to report third-quarter earnings this week.
Merck Partners with Promega to Advance 3-D Cell Drug Discovery Technologies
09:16am, Tuesday, 28'th Oct 2025
DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, has entered into a partnership with Promega Corporation, a global life science solutions and service leader based
RAHWAY, N.J.,--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces KEYTRUDA Plus WELIREG Met Primary Endpoint of DFS in Certain Patients With Clear Cell Renal Cell Carcinoma (RCC) Following Nephrectomy.
Merck-Eisai's cancer drug combo meets one main goal in late-stage study
06:43am, Tuesday, 28'th Oct 2025
Merck and Eisai's experimental combination treatment for a type of kidney cancer met one of the main goals in a late-stage study, the drugmakers said on Tuesday.
RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck and Eisai Announce WELIREG® Plus LENVIMA® Met Primary Endpoint of PFS in Certain Previously Treated Patients With Advanced Renal Cel
3 Dividend-Paying Drug Stocks to Buy at a Discount
02:00pm, Monday, 27'th Oct 2025
Pfizer currently has a 7% yield, and the company is making important business moves. Bristol Myers Squibb has a 5.6% yield and has been building its drug pipeline with acquisitions.
Are You Looking for a High-Growth Dividend Stock?
12:45pm, Monday, 27'th Oct 2025
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes?
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
12:06pm, Monday, 27'th Oct 2025
As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.
JNJ vs. MRK: Which Blue-Chip Pharma Stock Should Be in Your Portfolio?
10:21am, Monday, 27'th Oct 2025
J&J's diversified growth, strong pipeline, and robust balance sheet position it as a steadier long-term pick over Merck's Keytruda-dependent outlook.
